{"id":"NCT02969408","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma","officialTitle":"A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist \"Rescue\" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-13","primaryCompletion":"2018-02-02","completion":"2018-02-02","firstPosted":"2016-11-21","resultsPosted":"2019-05-03","lastUpdate":"2021-11-09"},"enrollment":397,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Albuterol Sulfate","otherNames":[]}],"arms":[{"label":"ABS eMDPI","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between albuterol sulfate (ABS) eMDPI and clinical asthma exacerbation (CAE) in adult participants at least 18 years of age with exacerbation-prone asthma. The ABS eMDPI dose will be 90 micrograms (mcg), 1 to 2 inhalations every 4 hours as needed, but participant dosing will not be limited to this dosing regimen. The purpose of this study is to evaluate the relationship between albuterol dosing and CAE.","primaryOutcome":{"measure":"Clinical Asthma Exacerbation (CAE) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CAE","timeFrame":"Baseline (Day 1) to Week 12","effectByArm":[{"arm":"ABS eMDPI","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":397},"commonTop":["Asthma"]}}